Aurinia Pharmaceuticals (AUPH) recently reached a settlement with Teva Pharmaceuticals over U.S. patents covering voclosporin capsules, setting December 7, 2036 as the earliest launch date for Teva’s potential generic, subject to FDA approval.

The settlement news appears to have aligned with a strong run in Aurinia Pharmaceuticals' shares, with a 7 day share price return of 13.77% and a year to date share price return of 12.51% at a last close of US$17.27. Over a longer window, the 3 year total shareholder return of 93.39% compared with a 1 year total shareholder return of 42.96% suggests momentum has been building rather than fading.

If this kind of move has you looking beyond a single biopharma stock, it could be a good moment to see which other companies are catching attention through the 40 healthcare AI stocks

The latest jump in Aurinia Pharmaceuticals could reflect investors reassessing the business after the Teva settlement, or it could be sentiment chasing recent returns. So how does the current valuation stack up against the fundamentals?

Most Popular Narrative: 17.8% Undervalued

According to the most followed narrative on Aurinia Pharmaceuticals, a fair value of $21.00 sits above the recent $17.27 share price. This frames the current move after the Teva settlement in valuation terms rather than just momentum.

Aurinia Pharmaceuticals (NASDAQ: AUPH) continues to prove that clarity can outperform complexity. With Lupkynis (voclosporin) as its single commercial asset for lupus nephritis, the company has turned concentration into discipline. Revenue is projected to grow between 16% and 21% this year, with EPS potentially doubling, signaling a shift from early commercialization to sustained profitability.

Want to see what sits behind that fair value for Aurinia Pharmaceuticals. The narrative leans heavily on revenue expansion, rising margins and a tighter earnings profile. Curious how those inputs are stitched together into a long term view.

Result: Fair Value of $21.00 (UNDERVALUED)

However, Aurinia Pharmaceuticals still faces concentration risk around Lupkynis and uncertainty around long dated aritinercept timelines, which could challenge this undervalued narrative.

Next Steps

If the mixed signals around Aurinia Pharmaceuticals leave you undecided, treat that as your cue to move quickly and review both sides of the story yourself. A balanced view means weighing potential downside against upside before making any call, so take a closer look at the 3 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Aurinia Pharmaceuticals?

Do not stop with Aurinia Pharmaceuticals if you want a stronger watchlist. Use the Simply Wall St screener to compare fresh ideas and pressure test your convictions.

• Target potential bargains that combine quality and value by scanning the market through the 50 high quality undervalued stocks.
• Strengthen your focus on resilience by checking companies picked out by the 79 resilient stocks with low risk scores.
• Get ahead of the crowd by reviewing the screener containing 18 high quality undiscovered gems before other investors catch on.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.